(Q85751466)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Katerina Kubackova

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Z Bortlicek

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

T Pavlik

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

B Melichar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Z Linke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

P Pokorna

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Vyzula

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Prausova

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Czech Renal Cancer Cooperative Group

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

12 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

385-392

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25304882%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11523-014-0343-8

21 February 2020

exact match

0 references

cites work

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

1 reference

12 December 2020

Interferon treatment of renal cell carcinoma. Current status and future prospects

1 reference

12 December 2020

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

12 December 2020

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

1 reference

12 December 2020

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.

1 reference

12 December 2020

Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).

1 reference

12 December 2020

1 reference

12 December 2020

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

1 reference

12 December 2020

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

12 December 2020

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

1 reference

12 December 2020

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

1 reference

12 December 2020

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

1 reference

12 December 2020